Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: AB Sciex; BioServe; Cellectis Plant Sciences; Cylene Pharmaceuticals, Horizon Discovery; GeneWiz; SeqGen, Illumina

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The US Food and Drug Administration has purchased eight AB Sciex QTrap 5500 Systems for use at its headquarters and seven field labs for analysis of the US food supply, AB Sciex said this week.


BioServe said this week that the Maine Medical Center's Tissue Bank has joined the BioServe Network, a collection of research and medical institutes that provide biomaterials for a biorepository run by the firm.


Cellectis Plant Sciences, the plant genome engineering subsidiary of French firm Cellectis, has licensed rights to Midwest Oilseeds' Aerosol Beam Injector technology for precise modification of plant genomes. The technology allows functional meganucleases to be delivered directly into plant cells, thus avoiding the need for DNA vectors.


Cylene Pharmaceuticals will use Horizon Discovery's X-Man human isogenic cancer cell lines to identify patients who will respond to its CK2 inhibitor, CX-4945, which is currently in Phase I studies. The San Diego-based biopharmaceutical company is developing the kinase inhibitor for treatment of multiple myeloma.


Genewiz said this week that it has expanded its DNA sequencing capabilities with the opening of a new lab in Cambridge, Mass. The South Plainfield, NJ-based firm said that the new lab will offer a variety of sequencing services, as well as gene synthesis, molecular biology, and other genomic services.


Torrance, Calif.-based SeqGen has signed an agreement to become an instrument service provider for Illumina's NexGen GAIIx analyzers.